Hints and tips:
...In a statement, Sandoz called AbbVie’s continued dominance “the epitome of a dysfunctional market”....
...Each Novartis investor will receive one Sandoz share for every five Novartis shares they hold....
...The ebullient Jean-Charles Boisset of Burgundy arrived at Raymond in 2009, Chanel Inc bought St Supéry in 2015 and the next year the Tesserons of Ch Pontet Canet in Bordeaux bought Robin Williams’ winery...
...Founded by the Sandoz family, the business merged with Ciba-Geigy to create Novartis in 1996....
...It also has a small direct holding in Astra Agro Lestari....
...The impact may not be immediate, according to an executive at Indonesian palm oil producer Astra Agro Lestari, who said lower harvests might only be seen two years after El Niño started....
...The case for splitting off Sandoz is not conclusive. A push by Narasimhan to make Sandoz’s manufacturing and other operations independent of Novartis is nearly complete....
Higher costs and debt pile make group’s push for a $10bn valuation less appetising
...The US consumer products giant says it sources “palm oil materials” from a wholesaler that buys in turn from the unit, Astra Agro Lestari....
...Last month a former Sandoz executive pleaded guilty to price-fixing....
...To boost supplies of antimalarials, generics manufacturers Teva and Novartis’ Sandoz have pledged to donate millions of doses to US hospitals....
...Mr Mamin said in a statement: “Tyson is a world-class company with the expertise necessary to help Kazakhstan jump-start the transformation of our agro-protein capabilities and help us create an ecosystem...
...However, in an interview with the Financial Times late last year, Mr Narasimhan insisted there was no plan to spin off Sandoz. “We’re committed to Sandoz....
...Rivals entering the market include Amgen, Sandoz, Biogen, Samsung Bioepis and Mylan. In the first quarter, Humira represented 56 per cent of revenue at $4.4bn....
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...So far, Mylan, Teva, Sandoz, and Amneal have issued press releases discussing plans to build significant amounts of inventory of hydroxychloroquine for treatment of COVID-19....
...Amgen, Sandoz, Mylan, and Samsung Bioepis launched copycat drugs in Europe two weeks ago. Prices differ between markets but are between 10 and 80 per cent cheaper....
...Amgen led the way in reaching an agreement with AbbVie that it would not launch its Humira substitute in the US until 2023, and Mylan, Samsung Bioepis and Sandoz have followed suit....
...Mr Harchowal said the relationship it had forged with Sandoz had opened up an entirely new way of working with drugmakers....
...A version of this article was first published by the Nikkei Asian Review on January 23. ©2019 Nikkei Inc. All rights reserved....
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
...He foresees a situation in which the company’s generics unit Sandoz — which has come under heavy pricing pressure in the US — could use such technologies “to add value to what are older medicines . . . in...
...Sales at Sandoz, the company’s generics business, fell 5 per cent, to stand at $2.5bn, the only part of the business to come in below analysts’ expectations....
...Rather, it is part of the mixed legacy of Daniel Vasella, the former Novartis patriarch who founded the company in 1996 by merging Ciba-Geigy with Sandoz....
...The talks come shortly after Novartis reported that pricing pressure hurt quarterly sales at Sandoz, its generics division....
International Edition